AMED

Japan Agency for Medical Research and Development

AMED

Driving seamless medical innovation — From basic research to real-world solutions, powered by eight integrated projects

We are fully committed to promoting research and development in the medical field, from basic research to practical application, through eight integrated projects.

The Japan Agency for Medical Research and Development (AMED) was established in 2015 as a funding agency that plays a central role in supporting research and development (R&D) in the medical field and fostering the necessary environment for research in Japan under the Japanese government's Healthcare Policy. Since AMED's establishment, we have consolidated national budgets related to research and development in the medical field, providing seamless support for R&D from basic research to practical applications.

Under the Third Medium- to Long-Term Plan (FY2025 - FY2029), AMED will further develop and promote R&D through eight integrated projects, designed around modalities (drug discovery, therapeutic approaches, etc.) established during the Second Medium- to Long-Term Plan. We will also continue to flexibly manage research and development related to specific disease areas across the integrated projects.

We will provide continuous and stable support for basic research to ensure the consistent creation of innovative drug seeds, and we will also accelerate the practical application of research outcomes by strengthening our exit-oriented approach. Across all integrated projects, we will strengthen support, promote medical digital transformation and AI drug discovery, and expand R&D internationally. In addition, we will develop support initiatives that connect projects across government ministries at each stage, from basic to applied and clinical research, including the transfer of technology seeds to companies with a view to social return on investment. We will also further promote social co-creation in medical research and development, such as patient/public involvement in research.

In preparation for future public health emergencies, we have launched a new Infectious Disease Project and have begun collaboration with relevant government agencies. We are working to improve systems for the development of vaccines, diagnostics, and therapeutics, including initiatives based on the "Strategy for Strengthening the Vaccine Development and Production System", which is associated with the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) established within AMED in 2022.

With the rapid diversification of modalities for treatment or diagnosis, there is a growing need to enhance integrated drug discovery through cross-disciplinary approaches and to accelerate the development of new modalities that are internationally competitive. We strive to promote AMED's overall projects and maximize outcomes from a global perspective by deepening collaboration with various domestic and overseas institutions, enhancing information gathering and dissemination, and promoting international joint research and personnel exchanges.

Taking the needs of patients, the medical community, researchers, industry, and other stakeholders into full account, we are committed to the advancement of medical care using world-class technologies, and to ultimately contributing to the formation of a society of healthy longevity.

NAKAGAMA Hitoshi, M.D., D.M. Sc.
President, Japan Agency for Medical Research and Development (AMED)

Japan Agency for Medical Research and Development (AMED)

Our mission

AMED plays a central role in supporting research and development in the medical field and putting in place the necessary environment for research. Our aim is to ensure that the outcomes of medical research and development are applied and delivered to patients and their families as soon as possible.



Overview

1. About AMED

The Japan Agency for Medical Research and Development (AMED) was established in 2015 as a funding agency that plays a central role in supporting R&D in the medical field and fostering the necessary environment for research. By promoting consistent R&D from basic to applied stages, our aim is to ensure that the outcomes of medical R&D are applied and delivered to patients and their families as soon as possible.

2. Organization

1) Executives

President: NAKAGAMA Hitoshi
Executive Director: YASHIKI Jirou
Auditors: KOMIYAMA Sakae, MAKI Kanetaka

2) Number of employees

746 personnel (as of January 1, 2025)

3. Budget (FY2025)

Annual budget: 123.2 billion yen
Adjustment budget: 17.5 billion yen*
*Appropriation of part of the Science and Technology Innovation Promotion Fund



Domestic Offices

- Department of Innovative Drug Discovery and Development (East Japan Office)
- Department of Innovative Drug Discovery and Development (West Japan Office)

Overseas Offices

- Washington, D.C. Office
- London Office



*Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response

Eight Integrated Projects

Project for Innovative Drug Discovery and Development

Promotes a wide range of research and development from drug discovery to clinical research and trials, as well as other initiatives that contribute to the creation of innovative new drugs and the enhancement of drug discovery R&D capabilities.

Project for Medical Device and Healthcare

Promotes research and development of medical device and healthcare technologies, using AI, IoT, etc. that provide advanced diagnosis and therapeutic capabilities, contributing to the prevention and treatment of diseases and improvements in quality of life, with an emphasis on practical applications and expansion into overseas markets.

Project for Regenerative Medicine and Cell and Gene Therapies

Promotes discovery and cultivation of innovative research seeds that have potential to become new medical technologies in the fields of regenerative medicine, and cell and gene therapies. Strengthens fundamental research and development with a view to practical application, and promotes clinical research and clinical trials of new medical technologies.

Project for Infectious Disease Research

Promotes research on a wide range of infectious diseases, including emerging and reemerging infectious diseases, to gain new knowledge and develop preventive measures and novel therapeutics. Promotes research and development, through SCARDA, that contributes to the development of new vaccines.

Project for Data Utilization and Life Course Research and Development

Promotes research and development that utilizes disease registries, and genome and cohort studies related to cancer, intractable diseases, and dementia, to contribute to the prevention of disease onset and progression, elucidation of disease mechanisms, and diagnosis and treatment from a life-course perspective. Promotes improvement of data infrastructure to accelerate the utilization of data in research and development in the medical field.

Project for Basic Research for Medical Innovation

Establishes an R&D system that transcends the organizational and disciplinary boundaries of academia to promote basic research, including the discovery and cultivation of groundbreaking research seeds for the creation of new medical modalities. Strengthens international collaborative research to enhance competitiveness and nurture early career researchers.

Project for Translational and Clinical Research Acceleration

Promotes the functions of the Center for the Creation of Innovative Medical Technology to provide consistent support to bridge the gap from basic research to the clinical trial stage. Supports the clinical research core hospitals to enhance capacities for implementation of global clinical trials.

Project for Medical Innovation Ecosystem

Strengthens R&D support for companies engaged in drug discovery, from pre-clinical to clinical trial stages, with hands-on support from venture capital investors. Promotes the establishment of a drug discovery ecosystem, by fostering research and development through collaboration among industry, academia, and government, aiming to create innovative pharmaceuticals and medical devices.



*R&D-related disease areas
The following areas intersect with each of the above integrated projects
Cancer / Intractable and rare diseases / Life course

International Collaboration

(as of July 2025)

1. East Asia Science and Innovation Area Joint Research Program (e-ASIA JRP)
2. International Collaborative Research Program for Tackling the NTDs (Neglected Tropical Diseases) Challenges in African Countries
3. Science and Technology Research Partnership for Sustainable Development (SATREPS)
4. Strategic International Collaborative Research Program (SICORP)
5. Research Program on the Challenges of Global Health Issues
6. U.S.-Japan Cooperative Medical Sciences Program (USJCMSP)
7. U.S.-Japan Cooperative Medical Sciences Program Collaborative Awards for Early-Stage and Female Scientists
8. Adopting Sustainable Partnerships for Innovative Research Ecosystem (ASPIRE)
9. Japan Program for Infectious Diseases Research and Infrastructure

International alliances

cdisc

Global Alliance for Genomics & Health
Collaborate. Innovate. Accelerate.

GLOPID-R

HIROs

HFSP International Human Frontier Science Program Organization

ICRP International Cancer Research Partnership

IRDiRC INTERNATIONAL RARE DISEASES RESEARCH CONSORTIUM

translation together

AMED at a glance



*This includes expenditures associated with various fund programs, in addition to the main budget allocation.



Applications, Awards, and Success Rates



FY2024

Applications
4,163

Awards
894

Success Rate
21.5%

R&D Projects



R&D Expenditure by Institution Type



*Based on data as of July 2025

Information

WEB site

The AMED website provides basic information on AMED along with details of medical research and development programs, calls for proposals, events, press releases, and achievements. Feel free to visit the website if you are interested in AMED projects or wish to learn the latest information on medical research.

https://www.amed.go.jp/en

YouTube

The AMED YouTube channel offers recordings of symposiums and conferences, as well as briefings on project applications and procedures, and explanatory videos on other aspects of our operations.

https://www.youtube.com/@amed

X

Our X feed provides up-to-date information on AMED and its activities, such as the launch of calls for proposals and selection outcomes, information on events, and other announcements from AMED.

https://x.com/amed_officialgl

Japan Agency for Medical Research and Development

Headquarters

Yomiuri Shimbun Bldg. 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan
Tel : +81-3-6870-2200

Department of Innovative Drug Discovery and Development (East Japan Office)

8F Muromachi Chibagin Mitsui Bldg, 1-5-5 Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-0022, Japan
Tel: +81-3-3516-6181

Department of Innovative Drug Discovery and Development (West Japan Office)

6F Midosuji Mitsui Bldg, 4-1-3 Bingomachi, Chuo-ku, Osaka-city, Osaka 541-0051, Japan
Tel: +81-6-6372-1771

Washington, D.C. Office

1920 L Street, Northwest, Suite 303, Washington, D.C. 20036, USA
Tel : +1 202-804-4056

London Office

3 Waterhouse Square, 138-142 Holborn London, EC1N 2SW, UK